<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypereosinophilic syndromes: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypereosinophilic syndromes: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypereosinophilic syndromes: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Florence Roufosse, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Klion, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hypereosinophilic syndromes (HES) are a group of rare disorders marked by the sustained overproduction of eosinophils, in which eosinophilic infiltration and mediator release cause damage to multiple organs. The urgency of treatment and choice of therapy is based on the patient's presentation, as well as laboratory findings and the results of mutational analysis.</p><p>The treatment and prognosis of HES will be reviewed here. The clinical features, pathophysiology, evaluation, and diagnosis of HES are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Some patients with HES require immediate treatment, while others can be safely monitored.</p><p class="headingAnchor" id="H1025378007"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The overall goals of therapy are reduction of the absolute eosinophil count (AEC), amelioration of signs and symptoms, and prevention of disease progression [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2334791105"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The urgency with which patients are treated depends on the severity of hypereosinophilia (HE) and the presence of signs and symptoms of the disease [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In rare instances, patients may present with extremely elevated eosinophil levels (eg, AEC above 100 x 10<sup>9</sup>/L [&gt;100,000 cells/microL]) or signs and symptoms of hyperleukocytosis. In these situations, hypercellularity should be rapidly reduced before additional treatments are considered. (See <a class="local">'Immediate treatment for severe disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of patients are symptomatic and have less severe degrees of eosinophilia. The goals of pharmacologic therapy are to reduce the signs and symptoms of eosinophilic disease and to maintain the AEC below 1.5 x 10<sup>9</sup>/L (1500 cells/microL) to help prevent the development of end-organ damage.</p><p></p><p class="headingAnchor" id="H2651770727"><span class="h2">Choice of initial therapy</span><span class="headingEndMark"> — </span>The choice of the initial therapeutic agent or agents for a given patient depends mainly on whether the patient has clinical features consistent with a myeloid disorder (eg, dysplastic eosinophils) with or without a <em>FIP1L1::PDGFRA</em> fusion. Patients with myeloid variants (eg, <em>PDGFRA</em>-positive HES) are treated initially with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate, while those with other types of HES are treated with an initial trial of glucocorticoids.</p><p class="headingAnchor" id="H2289464442"><span class="h2">Patients who can be observed initially</span><span class="headingEndMark"> — </span>Two groups of patients who can be safely managed with close observation are:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic familial eosinophilia – Familial eosinophilia with autosomal dominant transmission is described. Patients without clinical manifestations or evidence of organ involvement can be observed and monitored. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Familial HES'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypereosinophilia of unknown significance (HEus) – These patients present with asymptomatic but marked eosinophilia AEC &gt;1.5 x 10<sup>9</sup>/L (&gt;1500 cells/microL) and no evidence of clinical manifestations or organ involvement. HEus is not considered a form of HES, because eosinophil-mediated complications are absent.</p><p></p><p>Patients in these groups do not require therapy initially but should be monitored regularly for the development of clinical manifestations, since progression to more aggressive forms of HES can occur. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H351937905"><span class="h1">IMMEDIATE TREATMENT FOR SEVERE DISEASE</span></p><p class="headingAnchor" id="H591701112"><span class="h2">Indications for emergency treatment</span><span class="headingEndMark"> — </span>There are certain uncommon circumstances in which patients with hypereosinophilia (HE) should be treated immediately  (<a class="graphic graphic_algorithm graphicRef103933" href="/z/d/graphic/103933.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Extremely elevated eosinophil levels (eg, absolute eosinophil count [AEC] &gt;100 x 10<sup>9</sup>/L; &gt;100,000 cells/microL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs and symptoms of leukostasis (ie, pulmonary or neurologic dysfunction in the setting of a white blood cell count &gt;50 x 10<sup>9</sup>/L [&gt;50,000 cells/microL]). (See  <a class="medical medical_review" href="/z/d/html/4522.html" rel="external">"Hyperleukocytosis and leukostasis in hematologic malignancies", section on 'Clinical'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs and symptoms or other evidence of potentially life-threatening complications of HE (eg, acute heart failure, thromboembolic events). These can include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of likely developing eosinophil-mediated cardiac damage (based on either clinical findings or elevated serum troponin levels when cardiac impairment is not yet clinically evident).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thromboemboli, often of cardiac origin and arterial, can present as diffuse watershed central nervous system (CNS) infarctions or focal CNS thromboemboli (check for retinal hemorrhages and splinter hemorrhages) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with pulmonary involvement, computed tomography (CT) imaging of the chest demonstrating substantial eosinophil-associated disease (eg, extensive interstitial infiltrates, ground glass opacities, condensation) in concert with clinical symptoms can necessitate immediate treatment.</p><p></p><p class="headingAnchor" id="H2156099950"><span class="h2">Studies to obtain urgently</span><span class="headingEndMark"> — </span>Important tests to exclude other disorders in the differential diagnosis that can be obtained should be performed, particularly if glucocorticoid therapy is imminent, as therapy may alter the results. We suggest obtaining blood for the following studies before initiating therapy, although it is not necessary to wait for the results:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential to determine abnormalities of other cell lines. Absolute numbers of other white blood cells must be determined because relative percentages may be lowered in the setting of increased eosinophils.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood smear (to evaluate for immature white blood cells, dysplastic features that would suggest primary hematologic disorder) should be reviewed and kept for future reference.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tests of hepatic and renal function (for evidence of hepatic involvement or renal insufficiency).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Troponin (for evidence of subclinical eosinophil-associated myocarditis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B12 (elevated in myeloid variants of HES [M-HES], other myeloid neoplasms, and autoimmune lymphoproliferative syndrome [ALPS]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase (most consistently elevated in M-HES, variable in other subtypes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antineutrophil cytoplasmic antibodies (ANCA) for patients with features suggestive of eosinophilic granulomatosis with polyangiitis (EGPA), such as asthma and chronic rhinosinusitis with nasal polyposis. (See  <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte phenotyping by flow cytometry (may show abnormal T cell subsets in lymphocytic variants of HES [L-HES] or lymphoid malignancy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood for genetic analyses, namely <em>FIP1L1::PDGFRA</em> mutational analysis, <em>BCR::ABL1</em>, and T cell receptor (<em>TCR</em>) gene rearrangement studies (to detect T cell clonality as seen in peripheral T cell lymphoma or L-HES), although these are unaffected by glucocorticoid therapy.</p><p></p><p>When possible, it is also advisable to draw some extra samples of blood and serum to be frozen in case there are additional tests needed later or new etiologies or mutations are identified in the future for which the patient could be tested.</p><p>In addition to the tests listed above, we try to obtain:</p><p class="bulletIndent1"><span class="glyph">●</span>A bone marrow aspirate and biopsy prior to the administration of high-dose glucocorticoids, if possible, since glucocorticoids can alter the interpretation of these studies. Material should be obtained for cytogenetic analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high resolution chest CT or if not available, a chest radiograph (for evidence of pulmonary involvement).</p><p></p><p>Further evaluation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p class="headingAnchor" id="H441021690"><span class="h2">High-dose glucocorticoids</span><span class="headingEndMark"> — </span>High-dose intravenous glucocorticoid therapy is indicated for any of the situations outlined above. Intravenous dosing is preferred to ensure adequate drug delivery in patients who are acutely ill or have gastrointestinal involvement. (See <a class="local">'Indications for emergency treatment'</a> above.)</p><p>The mechanism of action of glucocorticoids in HES is not entirely clear. Glucocorticoids interfere with eosinophilopoiesis, but this is unlikely to account for the observation that eosinopenia may occur as early as four hours after glucocorticoid administration [<a href="#rid4">4</a>]. Accelerated apoptosis and/or sequestration of eosinophils may also play a role [<a href="#rid5">5</a>].</p><p>It is critical to assess the patient's risk of <em>Strongyloides</em> infection prior to the administration of glucocorticoids, since glucocorticoids can precipitate potentially fatal dissemination in infected patients.</p><p class="headingAnchor" id="H702433233"><span class="h3">Assess for risk of Strongyloides infection</span><span class="headingEndMark"> — </span>Prior to the administration of glucocorticoids, the patient's risk of <em>Strongyloides</em> infection must be assessed, since glucocorticoids can precipitate potentially fatal dissemination in infected patients (hyperinfection syndrome). Individuals with any potential exposure to <em>Strongyloides </em>should be treated empirically for strongyloidiasis with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> (200 mcg/kg daily for two days). This may be given concomitantly with glucocorticoids, since the latter should not be delayed. <em>Strongyloides</em> is endemic in tropical and subtropical regions (ie, bordering the tropical regions to the north or south) worldwide and occurs sporadically in temperate areas. In the United States, the highest rates of infection are among residents from rural areas of the southeastern states. All at-risk individuals should be treated, even if the serology is negative, because the reliability of serologic testing is variable, and stool examination for larvae is insensitive. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Serology'</a>.)</p><p class="headingAnchor" id="H1460998593"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>High-dose intravenous glucocorticoids are initiated at doses ranging from 1 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to 1 gram of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>. For most patients, 1 mg/kg of prednisone is appropriate, but if the clinical presentations and associated complications are acute and life-threatening, pulses of 1 gram of methylprednisolone should be administered for one to two days.</p><p class="headingAnchor" id="H702433251"><span class="h3">Expected response</span><span class="headingEndMark"> — </span>In response to high-dose glucocorticoids, the eosinophil count typically either drops dramatically (eg, by more than 50 percent of the original value) within 24 hours or remains the same (no response).</p><p>Most patients who respond can be stabilized within one week. If there is minimal initial response, then glucocorticoids alone are unlikely to be effective for that patient, although glucocorticoids are usually continued until a second agent has been added and a decrease in blood eosinophil count is seen.</p><p class="headingAnchor" id="H92634036"><span class="h2">Acute therapies in steroid-unresponsive patients</span><span class="headingEndMark"> — </span>For patients with features of EGPA (ie, asthma, sinus disease, pulmonary infiltrates) and severe organ involvement (cardiac, renal, neurologic) who are unresponsive to glucocorticoids, we favor treatment with either <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis", section on 'Severe EGPA'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interventions</strong> – Other agents besides <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> that have been used to acutely reduce eosinophil counts in a small number of cases include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imatinib</strong><strong> mesylate</strong> – At doses of 400 mg daily, this agent may be effective in some steroid-refractory patients, since these patients may have <em>FIP1L1::PDGFRA</em>-positive HES or another mutation involving an imatinib-sensitive tyrosine kinase, and it is relatively less toxic than <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>. <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">Imatinib</a> must be administered in conjunction with glucocorticoids in patients with evidence of cardiac involvement (eg, elevated serum troponin suggesting myonecrosis). A response typically occurs within one to several days in <em>FIP1L1::PDGFRA</em>-positive patients but may only be apparent after several weeks in <em>FIP1L1::PDGFRA</em>-negative patients. (See <a class="local">'Imatinib mesylate'</a> below and <a class="local">'Concomitant glucocorticoids in patients with cardiac disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vincristine</strong> – The cytoreductive agent <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> has been administered at doses of 1 to 2 mg/m<sup>2</sup> intravenously, weekly to monthly, in a subset HES patients requiring urgent therapy, ie, those with extremely elevated blood leucocytes and those with signs/symptoms of leukostasis [<a href="#rid8">8</a>]. Glucocorticoids are continued when vincristine is added. In responsive patients, eosinophil counts begin to fall within hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hydroxyurea</strong> – In patients who fail to respond to high-dose glucocorticoids, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> may be administered orally at an initial dose of 500 to 1000 mg/day and quickly increased to 2000 mg/day, as tolerated, if the response is suboptimal. Of note, a response to this agent can take one to two weeks to become evident. High-dose hydroxyurea (50 to 100 mg/kg as a single dose; maximum dose 6 grams) can be used to rapidly lower eosinophil counts in patients with eosinophilia &gt;100 x 10<sup>9</sup>/L who do not respond to glucocorticoid therapy. (See <a class="local">'Hydroxyurea'</a> below.)</p><p></p><p>Once the patient has stabilized and eosinophil counts are lowered, a full evaluation can proceed, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Evaluation and diagnosis'</a>.) </p><p class="headingAnchor" id="H2459831106"><span class="h1">NON-EMERGENCY TREATMENT</span><span class="headingEndMark"> — </span>For patients who do not require immediate therapy, the first decision is whether to initiate therapy or simply monitor the patient at regular intervals. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H2374192181"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Symptomatic patients and those with evidence of end-organ damage should be initiated on therapy. The choice of therapy depends primarily on the disease variant  (<a class="graphic graphic_table graphicRef116201" href="/z/d/graphic/116201.html" rel="external">table 1</a>) [<a href="#rid9">9</a>].</p><p>Patients with known or suspected imatinib-sensitive variants (eg, most commonly <em>PDGFRA</em>-positive myeloid variants of HES [M-HES]) are treated initially with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate (with concomitant glucocorticoids if there is evidence of cardiac involvement), while those with other types of HES, such as lymphocytic variants of HES (L-HES) or idiopathic HES, are initially treated with glucocorticoids alone.</p><p class="headingAnchor" id="H529900572"><span class="h2">Myeloid variants</span><span class="headingEndMark"> — </span>Patients with M-HES have clinical features consistent with a myeloid disorder or have a specific gene mutation (eg, <em>FIP1L1::PDGFRA</em> fusion). (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Myeloproliferative HES variants'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">PDGFRA-positive HES</span><span class="headingEndMark"> — </span>Patients with <em>PDGFRA</em>-positive HES often have an aggressive course with disabling complications and high mortality in the absence of treatment. However, this is not universal, and case reports describe patients presenting with minimal symptoms (eg, cough) in whom the disease did not progress for several years [<a href="#rid10">10</a>]. Conversely, it cannot be assumed that patients with mild disease do not have the <em>FIP1L1::PDGFRA</em> mutation. Thus, a more nuanced understanding of the clinical significance of the <em>FIP1L1::PDGFRA</em> mutation is developing over time.</p><p>First-line therapy for all patients with the <em>FIP1L1::PDGFRA</em> mutation is the tyrosine kinase inhibitor, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate. This should be offered to all patients. Treatment should be initiated as soon as the diagnosis is established to prevent progression of cardiac disease and other severe end-organ damage. If mutational analysis is not available and treatment is required, the presence of a markedly elevated serum B12 level (&gt;2000 pg/mL) and/or an elevated serum tryptase level (&gt;11.5 ng/mL) and/or splenomegaly can be a marker for the presence of the <em>FIP1L1::PDGFRA</em> mutation [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H10"><span class="h4">Imatinib mesylate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">Imatinib</a> mesylate is a potent inhibitor of ABL, KIT, PDGFRA, and platelet-derived growth factor receptor beta (PDGFRB) kinase activities [<a href="#rid12">12,13</a>]. It induces disease remission and prevents progression of disease in sensitive patients. Patients with potential cardiac disease, as assessed by elevated serum troponin levels and/or abnormalities on echocardiography, should receive concomitant glucocorticoids when therapy with imatinib is initiated to prevent acute necrotizing myocarditis. (See <a class="local">'Concomitant glucocorticoids in patients with cardiac disease'</a> below.)</p><p>The FIP1L1::PDGFRA fusion is exquisitely sensitive to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, and doses required to induce molecular remission are lower than those used for treating chronic myeloid leukemia (CML). Studies have demonstrated clinical, hematologic, and molecular remission in the majority of patients with <em>FIP1L1::PDFGRA</em>-associated HES who are treated with imatinib [<a href="#rid12">12,14-22</a>]. Clinical symptoms due to hypereosinophilia (HE) resolve and eosinophil counts normalize generally within one to two weeks. In contrast, cardiac symptoms due to structural abnormalities resulting from endomyocardial fibrosis and fixed neurologic deficits may not improve with imatinib therapy [<a href="#rid17">17,23,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Clinical features'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective review of patients with glucocorticoid-resistant <em>FIP1L1::PDGFRA</em>-positive myeloid neoplasm reported complete hematologic response (CHR) in all 148 patients treated with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>; all 84 patients who were monitored by molecular testing achieved complete molecular response [<a href="#rid25">25</a>]. Among 46 patients who discontinued imatinib, 57 percent relapsed. Rates of overall survival (OS) at 1, 5, and 10 years were 99, 95, and 84 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective multicenter study of 72 Italian patients with idiopathic or primary HES, 63 were treated with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, 100 to 400 mg/day [<a href="#rid21">21</a>]. Of the 63 male patients, 27 carried the <em>FIP1L1::PDGFRA</em> rearrangement. These 27 achieved CHR and remained in remission at the time of publication (median follow-up of 25 months). Treatment was continued indefinitely at doses of 100 to 400 mg/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other retrospective studies also reported robust responses to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> [<a href="#rid16">16,26</a>]. </p><p></p><p>Because HES requires lower doses of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> than CML, dose-related side effects, such as myalgia, peripheral edema, and diarrhea, are uncommon in patients with HES. However, serious complications requiring immediate interruption of treatment have been reported and include neutropenia, life-threatening myocarditis, and hepatic necrosis [<a href="#rid15">15,20,23,27</a>]. Imatinib therapy can usually be reinitiated once the complication has resolved [<a href="#rid28">28</a>]. (See <a class="local">'Concomitant glucocorticoids in patients with cardiac disease'</a> below.)</p><p>Primary resistance to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> in patients with the <em>FIP1L1::PDGFRA</em> mutation has been uncommonly reported [<a href="#rid29">29</a>]. In one patient, two point mutations were detected in the <em>PDGFRA</em> domain, the functional significance of which has not been explored [<a href="#rid30">30</a>]. Secondary resistance is discussed below. (See <a class="local">'Imatinib-resistant disease'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h5">Dosing</span><span class="headingEndMark"> — </span>Understanding of the most appropriate dose and duration of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> therapy is evolving. We suggest an initial dose of 400 mg per day, given orally. Typically, symptoms improve, and eosinophil counts normalize within one to two weeks after initiation of imatinib. In patients who do not respond within two to four weeks, imatinib should be discontinued and other therapies considered. For those who respond, the maintenance therapy is administered at a reduced dose. (See <a class="local">'Maintenance therapy'</a> below.)</p><p>Initial doses of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> as low as 100 mg daily (or even weekly) have proven effective in controlling the eosinophilia and clinical symptoms in most patients with the <em>FIP1L1::PDGFRA</em> mutation [<a href="#rid31">31-33</a>], although molecular evidence of the <em>FIP1L1::PDGFRA</em> mutation may persist on low-dose therapy [<a href="#rid20">20,34</a>]. Experience with imatinib in the treatment of CML suggests that clinical relapse is more common in patients with detectable residual disease, and so initiating therapy at a higher dose (400 mg daily) may be preferred.</p><p class="headingAnchor" id="H12"><span class="h5">Concomitant glucocorticoids in patients with cardiac disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">Imatinib</a> is generally well tolerated. However, patients with HES and cardiac involvement, as assessed by echocardiographic evidence of myocarditis and/or elevated serum troponin levels, may be at risk for left ventricular dysfunction and cardiogenic shock when imatinib treatment is initiated. Presumably, the mechanism involves massive release of eosinophil granule proteins and subsequent damage to the myocardium, although this has not been conclusively demonstrated. Heart failure was reportedly reversible with prompt institution of systemic glucocorticoids, intensive support, and discontinuation of imatinib [<a href="#rid15">15,23</a>]. Therefore, concomitant treatment with systemic glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 to 2 mg/kg daily or equivalent) for one to two weeks when imatinib is initiated is recommended for patients with any evidence of cardiac involvement (even limited to asymptomatic elevations in troponin levels) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3133669"><span class="h5">Family planning</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">Imatinib</a> is a potential teratogen, although data are limited and mostly come from the use of imatinib in the setting of CML. Preclinical studies have reported teratogenicity of imatinib in some animals but not others [<a href="#rid35">35</a>]. Human case reports have described significant congenital abnormalities in the offspring of some women treated with imatinib, and women are advised to take measures to avoid pregnancy while taking this agent [<a href="#rid36">36</a>]. Imatinib is also contraindicated in lactating women. </p><p class="bulletIndent1"><span class="glyph">●</span>We advise male patients who require <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> that it may cause oligospermia and reduced fertility, although it is unclear how often this occurs [<a href="#rid35">35,37,38</a>]. The available data regarding men receiving imatinib for CML are mostly reassuring, and successful pregnancies have been reported [<a href="#rid39">39,40</a>]. If a male patient's female partner becomes pregnant, the patient should use barrier protection in order to limit exposure of the developing fetus to imatinib.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women requiring <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, we advise effective contraception to prevent pregnancy [<a href="#rid39">39</a>]. Whether imatinib therapy will affect future fertility in women is unknown. Primary ovarian insufficiency associated with imatinib therapy has been described in a case report [<a href="#rid41">41</a>]. For women who do become pregnant while taking imatinib, advice is more difficult. Some couples have decided on therapeutic termination of the pregnancy, others have continued treatment throughout the pregnancy, and still others have discontinued imatinib and were treated with other agents (eg, interferon) during the remainder of the pregnancy, with reinstitution of imatinib following delivery [<a href="#rid36">36,42</a>]. It may also be possible to discontinue imatinib therapy once the patient has entered remission. (See <a class="local">'Maintenance therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H13"><span class="h5">Maintenance therapy</span><span class="headingEndMark"> — </span>Once symptoms improve and eosinophil counts normalize, which usually occurs within one to two weeks after initiation of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, the dose should be reduced to the lowest effective dose that maintains suppression of polymerase chain reaction (PCR)-detectable <em>FIP1L1::PDGFRA</em> transcript levels, as well as blood eosinophilia. This dose is then continued for several years.</p><p>Although early reports suggested that reducing or stopping <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> in patients with the <em>FIP1L1::PDGFRA</em> mutation resulted in return of transcripts in at least 50 percent of patients [<a href="#rid22">22,34,43,44</a>], a subsequent study suggested that patients who achieve complete molecular remission and continue imatinib therapy for a prolonged period (ie, ≥7 years) are less likely to relapse after imatinib discontinuation [<a href="#rid45">45</a>]. This is consistent with observations in CML. The optimal duration of therapy has not been determined, but we suggest continuing imatinib therapy for at least seven years. </p><p>The strategy used to determine a maintenance therapy dose differs depending on the resources available. <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">Imatinib</a> 100 mg daily is frequently employed for maintenance when cost is not limiting. If cost is an issue, the dose may be gradually reduced (eg, to 100 mg every other day, then 100 mg twice per week, and then 100 mg weekly). If the gene transcript reappears, the dose should be increased to the last dose that suppressed it. Molecular remission should then be confirmed again.</p><p class="headingAnchor" id="H14"><span class="h4">Imatinib-resistant disease</span><span class="headingEndMark"> — </span>A few cases of acquired resistance to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> among <em>FIP1L1::PDGFRA</em>-positive patients have been reported. Testing for resistance mutations in blood or bone marrow is commercially available [<a href="#rid46">46</a>]. These were most commonly associated with a single base (T6741) substitution in the imatinib-binding portion of the kinase, similar to the T3151 mutation in <em>ABL</em> described in imatinib-resistant CML [<a href="#rid12">12,20</a>]. A second mutation, D842V, which is known to cause imatinib resistance in gastrointestinal stromal tumors associated with <em>PDGFRA</em> mutations, has also been reported in <em>FIP1L1::PDGFRA</em>-positive HES [<a href="#rid47">47</a>]. The best approach to managing patients with acquired imatinib resistance has not been extensively studied, although options include increasing the dose of imatinib, use of other tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a> or <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a>), or allogeneic hematopoietic cell transplantation (HCT). If not already pursued, referral to a center with expertise in HES should be arranged. (See <a class="local">'Hematopoietic cell transplantation'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h5">Other tyrosine kinase inhibitors</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> is the only commercially available tyrosine kinase inhibitor with proven activity in HES, several agents with activity against PDGFR, including <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a>, are available for other clinical use [<a href="#rid12">12,48-50</a>]. Nilotinib was studied in a phase 2 trial that included 12 patients with HES [<a href="#rid51">51</a>]. Sorafenib showed efficacy in a case report of imatinib-resistant HES, although the duration of response was short-lived [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/4496.html" rel="external">"Overview of the treatment of chronic myeloid leukemia", section on 'Treatment of disease resistance or drug intolerance'</a>.)</p><p class="headingAnchor" id="H323159387"><span class="h3">Other myeloid variants</span><span class="headingEndMark"> — </span>Some patients with HES and features of myeloid disease have responded to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> despite a negative test for the <em>FIP1L1::PDGFRA</em> mutation [<a href="#rid12">12,52-54</a>]. These individuals usually have an aggressive clinical course, dysplastic eosinophils in the peripheral blood, and bone marrow findings consistent with chronic myeloid disease. Some cases have mutations involving <em>PDGFRA</em> or <em>PDGFRB</em> with other fusion partners [<a href="#rid53">53-55</a>]. While testing for these alternative mutations is not widely available, the vast majority of patients with <em>PDGFRB</em> mutations will have translocations involving 5q31-33, including t(5;12) [<a href="#rid54">54</a>]. Imatinib therapy may be considered for patients presenting with HES and features of myeloid disease (ie, after an initial glucocorticoid challenge but before any other therapeutic intervention). In one study, the response rate was 54 percent in patients with four or more features of myeloproliferative disease [<a href="#rid45">45</a>].</p><p>The starting dose of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> is 400 mg daily. Responses may be slower than in <em>PDGFRA</em>-positive disease, and dose escalation up to 800 mg daily may be considered in patients with inadequate response [<a href="#rid56">56</a>]. In patients who do not respond within one to three months, imatinib should be discontinued and other therapies considered, such as <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> or interferon alfa. Otherwise healthy patients with treatment refractory HES may be candidates for allogeneic HCT. (See <a class="local">'Steroid-sparing and second-line therapies'</a> below and <a class="local">'Hematopoietic cell transplantation'</a> below.)</p><p>Several small reports have described the activity of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> in the treatment of patients with myeloid neoplasms with a <em>PDGFRB</em> fusion gene [<a href="#rid57">57-59</a>]. As an example, a retrospective analysis of 26 patients with myeloid neoplasms with <em>PDGFRB</em> rearrangements treated with imatinib (100 to 400 mg daily) and followed for a median of 10.2 years reported an overall response rate of 96 percent [<a href="#rid52">52,54</a>]. Most patients who achieved a hematologic response did so within two months, suggesting that a three-month trial was sufficient. At the time of publication, no relapses had occurred in the 13 patients who achieved a complete cytogenetic response or in the 8 patients who achieved a molecular remission. The estimated progression-free survival at six years was 88 percent. Two patients died: one of invasive fungal infection after transformation to blast crisis, and one of intracranial hemorrhage due to thrombocytopenia.</p><p><em>PDGFRB</em>-associated myeloid neoplasms usually present with features consistent with chronic myelomonocytic leukemia (CMML). Although peripheral eosinophilia can be marked, eosinophilic end-organ manifestations are uncommon. The clinical presentation and management of <em>PDGFRB</em>-associated myelodysplastic/myeloid neoplasms (MDS/MPN) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'MDS/MPN'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">HES without myeloid features</span><span class="headingEndMark"> — </span>HES without myeloid features includes T cell lymphocytic variants (L-HES) and idiopathic HES  (<a class="graphic graphic_table graphicRef116201" href="/z/d/graphic/116201.html" rel="external">table 1</a>). Glucocorticoids are the initial therapy of choice for patients with organ involvement who do <strong>not</strong> have the <em>FIP1L1::PDGFRA</em> fusion or another imatinib-sensitive tyrosine kinase mutation (eg, <em>PDGFRA</em> with other fusion partners).</p><p>Second-line therapies are used for patients whose disease has not responded to glucocorticoids or in combination with glucocorticoids as steroid-sparing agents. (See <a class="local">'Steroid-sparing and second-line therapies'</a> below.)</p><p class="headingAnchor" id="H2569606106"><span class="h3">When to treat</span></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic patients or those with evidence of end-organ damage should be initiated on therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with intermittent symptoms, such as angioedema, urticaria, and gastrointestinal symptoms, can be treated with short courses of glucocorticoids, as needed, if the interval between flares is long [<a href="#rid60">60</a>]. (See <a class="local">'Monitoring for organ involvement'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic patients (hypereosinophilia of undetermined significance [HE<sub>US</sub>], familial eosinophilia) or those with very mild or recurrent symptoms with long disease-free intervals need not necessarily be treated, but should be monitored every three (at the beginning) to six months for the development of organ involvement and watched for signs and symptoms of cardiovascular and thrombotic complications.</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is the primary initial therapy for symptomatic <em>FIP1L1::PDGFRA</em>-negative HES without indications for emergency treatment. Appropriate starting doses range from 20 to 60 mg daily, depending on the severity of the disease manifestations and the degree of eosinophilia at presentation. The dose should be adjusted once the patient responds. (See <a class="local">'Adjusting therapy after initial response'</a> below.)</p><p>Prior to administration of glucocorticoids, the clinician must assess the risk of <em>Strongyloides</em> infection and treat any patients with possible exposure with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>. (See <a class="local">'Assess for risk of Strongyloides infection'</a> above.)</p><p>If the eosinophil count does not respond within one week to the initial dose, the dose should be increased. Higher doses (eg, intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, 1 gram daily or 15 mg/kg/day) can be administered for a few days, and some patients may require very high doses initially. However, this dose is too toxic for extended use, and alternative steroid-sparing regimens should be planned. (See <a class="local">'Steroid-sparing and second-line therapies'</a> below.)</p><p class="headingAnchor" id="H1115483494"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>A few studies have provided information about the efficacy of glucocorticoids.</p><p class="bulletIndent1"><span class="glyph">●</span>In a large series of 188 HES patients, 75 percent received glucocorticoids alone as initial therapy, and partial or complete remission was achieved in 85 percent at one month [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study of 164 patients with <em>FIP1L1::PDGFRA</em>-negative HES, 90 percent of the group responded to glucocorticoids, where response was defined as a reduction of the absolute eosinophil count (AEC) to &lt;1000 cells/microL and control of symptoms [<a href="#rid9">9</a>]. The disease variant was the best and only predictor of response to glucocorticoids. Patients with idiopathic HES or overlap HES (single organ involvement or HES with features of eosinophilic granulomatosis with polyangiitis [EGPA]) were more responsive than those with M-HES or L-HES  (<a class="graphic graphic_table graphicRef116201" href="/z/d/graphic/116201.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H351937108"><span class="h4">Adjusting therapy after initial response</span><span class="headingEndMark"> — </span>Once blood eosinophilia is suppressed and symptoms are controlled, daily glucocorticoid doses are gradually reduced to the lowest dose that maintains control of the eosinophil count and clinical manifestations. In the large series mentioned previously, patients were able to reduce the dose of glucocorticoids to a median dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> of 10 mg per day [<a href="#rid26">26</a>]. However, 42 percent of 179 patients who were initially treated with glucocorticoids discontinued them, either because of disease resistance or adverse effects. </p><p>The tapering schedule is highly variable and should be guided by the severity of the presenting clinical complications and the extent to which eosinophil suppression has been achieved by treatment. Doses can be tapered more rapidly in patients with complications that are not life-threatening and in those whose eosinophil levels plummet dramatically after initiation of glucocorticoids. Eosinophil levels and clinical manifestations should be monitored weekly at the beginning of therapy, changing to progressively longer intervals depending on the response.</p><p class="headingAnchor" id="H18"><span class="h4">Addition of steroid-sparing agents</span><span class="headingEndMark"> — </span>Once a stable maintenance dose of glucocorticoids has been reached, the dose may be reduced further by introducing a second steroid-sparing agent. We suggest adding a steroid-sparing agent if the patient requires more than 10 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> daily or demonstrates significant side effects from glucocorticoid therapy. Selection of a steroid-sparing agent is discussed below. </p><p class="headingAnchor" id="H19"><span class="h2">Steroid-sparing and second-line therapies</span></p><p class="headingAnchor" id="H2944250957"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>Selection of a second-line or steroid-sparing agent is informed by pathologic/molecular features, toxicity profile, comorbid conditions, availability, and cost. No studies have directly compared various agents regarding outcomes and toxicity, and no agent is optimal for all patients. Our approach to the choice of agent follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected myeloid malignancy</strong> – For patients with myeloproliferative features suggestive of a myeloid malignancy, we generally treat with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>. </p><p></p><p class="bulletIndent1">For patients who do not respond adequately to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, we favor treatment with <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>. Where mepolizumab is not available or for patients who do not respond after three to six months of mepolizumab treatment, other options include <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, interferon alfa, and kinase inhibitors (eg, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>); these agents are usually administered in conjunction with glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonal T cells (eg, L-HES)</strong> – For patients with abnormal clonal T cells (eg, L-HES), we favor treatment with <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, although the responses are not as robust as with myeloid malignancies [<a href="#rid61">61,62</a>]. If mepolizumab is not available, addition of interferon alfa to glucocorticoid therapy is an acceptable alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – For other patients, we favor treatment with <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> (where available and if patients fulfill eligibility criteria), <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, interferon alfa, or <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>. </p><p></p><p>For patients who do not respond adequately to several pharmacologic agents, allogeneic HCT may be considered.</p><p class="headingAnchor" id="H1527675316"><span class="h3">Mepolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">Mepolizumab</a> is a monoclonal antibody directed against interleukin-5 (IL-5), a growth factor that is critical for eosinophil maturation, activation, and survival. Mepolizumab can be beneficial in glucocorticoid-sensitive HES, including idiopathic HES, lymphocytic variants of HES (L-HES), and HES/eosinophilic granulomatosis with polyangiitis (EGPA) overlap [<a href="#rid1">1</a>]. </p><p><a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">Mepolizumab</a> 300 mg (given as three separate 100 mg injections) is administered subcutaneously once every four weeks; note that this dosing is significantly higher than that approved for asthma. Mepolizumab is generally well-tolerated.</p><p><a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">Mepolizumab</a> was shown to be an effective, well-tolerated agent in a multicenter, placebo-controlled, phase 3 trial of 108 patients with <em>FIP1L1::PDGFRA</em>-negative HES [<a href="#rid63">63</a>]. Patients with ≥2 disease flares in the past 12 months and a baseline absolute eosinophil count of at least 1000/microliter were randomly assigned to receive subcutaneous mepolizumab (300 mg) versus placebo every four weeks for 32 weeks, in addition to their existing stable HES therapy. Compared with placebo, mepolizumab was associated with a lower percentage of patients experiencing a subsequent disease flare (28 versus 56 percent of patients); mepolizumab was also associated with a 66 percent reduction in the annualized flare rate and in risk of experiencing a flare. Similar proportions of patients in the mepolizumab and placebo groups experienced on-treatment adverse events (89 versus 87 percent, respectively). Another placebo-controlled phase 3 trial [<a href="#rid64">64</a>] and other reports [<a href="#rid61">61,65-68</a>] also demonstrated efficacy of mepolizumab as a long-term steroid-sparing agent in HES. </p><p><a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">Mepolizumab</a> is approved for treatment of EGPA in adults by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment of HES of ≥6 month duration without an identifiable non-hematologic cause in adults and children ≥12 years [<a href="#rid69">69</a>]. </p><p class="headingAnchor" id="H20"><span class="h3">Hydroxyurea</span><span class="headingEndMark"> — </span>For patients who have neither L-HES or myeloid features or who are not eligible for <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is a preferred second-line agent. Hydroxyurea has a favorable toxicity profile, low cost, and good efficacy.</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> suppresses eosinophilopoiesis and is usually added to glucocorticoids if steroid toxicity has become dose-limiting or less commonly, used as monotherapy when glucocorticoids have failed [<a href="#rid26">26</a>]. It is administered orally at an initial dose of 500 to 1000 mg/day and increased to 2000 mg/day, as tolerated. Hydroxyurea has relatively few side effects compared with other chemotherapeutic agents, although hematologic toxicity (including thrombocytopenia and anemia) and gastrointestinal side effects may become issues at higher doses [<a href="#rid70">70,71</a>]. Patients should use contraception because hydroxyurea is a teratogen. In HES, this agent is usually given in combination with other agents.</p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective study, combined therapy with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> (2000 mg per day) and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg/day) was administered to 18 patients with <em>FIP1L1::PDGFRA</em>-negative HES, except for three patients who were refractory to glucocorticoid therapy prior to the trial [<a href="#rid71">71</a>]. Among the 15 patients treated with this combination, 9 had a complete response, and 6 had a partial response. After an initial response was observed, doses were tapered progressively, and in most patients, disease was controlled with low-dose hydroxyurea (500 to 1000 mg daily) as a single agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 188 patients, 36 patients were treated with the combination of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> and glucocorticoids, and 25 (69 percent) responded [<a href="#rid26">26</a>]. Of those 18 patients treated with hydroxyurea alone, 13 responded partially or completely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study found that low-dose <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> potentiated the effect of interferon alfa in some patients [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Interferon alfa</span><span class="headingEndMark"> — </span>In settings where <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> is not available or in patients not eligible for treatment with mepolizumab, conventional interferon alfa or pegylated interferon alfa are acceptable as second-line therapy for patients with HES who do not respond to glucocorticoids or are GC-dependent and require unacceptable dosing and/or experience toxicity. (See <a class="local">'Choice of therapy'</a> above.)</p><p>In patients who respond only to higher doses of glucocorticoids, interferon alfa is added as a steroid-sparing agent. We usually use it together with low-dose glucocorticoids in patients with L-HES because of a theoretical risk (based on in vitro data) that interferon alfa alone could lead to expansion of the abnormal T cell clones [<a href="#rid73">73</a>], but this has not been observed in practice. Side effects of interferon alfa include dose-dependent, flu-like symptoms, depression, peripheral neuropathy, fatigue, thyroid dysfunction, induction of autoantibodies, and increased liver transaminases. The interferon dose should be reduced if cytopenias develop or liver enzymes increase and should be discontinued for severe depression. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon alfa</strong> – Doses of interferon alfa for treatment of HES range from 1 to 4 million units per dose subcutaneously, three to seven times weekly. Although the optimal schedule for administration has not been defined, a sample approach is to initiate treatment with 1 million units per injection daily and increase by 0.5 to 1 million units per injection every two weeks until the desired effect is reached or intolerance precludes further escalation. It may take several months to reach the effective dose.  </p><p></p><p class="bulletIndent1">Interferon alfa has been effective in several case series [<a href="#rid62">62,74-79</a>]. In a series of 188 patients, 46 patients received interferon alfa, most with glucocorticoids; response rates to combination therapy and monotherapy were 75 and 50 percent, respectively [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pegylated interferon alfa</strong> – Pegylated interferon alfa 2a (peginterferon) is associated with efficacy and toxicity that are similar to interferon alfa, but it requires only weekly treatment. </p><p></p><p class="bulletIndent1">Treatment of seven patients with L-HES with peginterferon (beginning at 45 to 90 micrograms subcutaneous weekly, increasing to a maximum of 180 micrograms weekly) was associated with improved symptoms in all seven; six of the seven patients had a sustained, steroid-free response for a median of 31 months and resolution of eosinophil-related end organ damage [<a href="#rid80">80</a>]. The population of aberrant T cells decreased in all of the patients and four had normalization of their T cell immunophenotype.</p><p></p><p class="bulletIndent1">The mechanism of action of interferon alfa in HES has not been fully elucidated, although it may involve inhibition of eosinophil differentiation and proliferation and promotion of development of Th1 T-helper lymphocytes [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H370697335"><span class="h3">Imatinib</span><span class="headingEndMark"> — </span>Some patients with HES and features of myeloid disease have responded to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> despite a negative test for the <em>FIP1L1::PDGFRA</em> mutation. A two- to four-week trial of imatinib therapy may be considered in patients presenting with HES and features of myeloid disease (ie, after an initial glucocorticoid challenge but before any other therapeutic intervention). One study found a response rate of 54 percent when four or more features of myeloproliferative disease were present [<a href="#rid45">45</a>]. Glucocorticoids should be continued during this trial in patients with potential cardiac disease, as assessed by elevated serum troponin levels and/or abnormalities on echocardiography. (See <a class="local">'Other myeloid variants'</a> above.)</p><p>In contrast to the subgroups above, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> does <strong>not</strong> appear to be useful in treating L-HES or D816V c-kit mutation-positive systemic mastocytosis with eosinophilia and should not be used in these patients [<a href="#rid81">81-84</a>]. (See  <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis", section on 'Imatinib'</a>.)</p><p class="headingAnchor" id="H349008949"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Other agents that have been used in steroid-unresponsive HES (excluding patients with the <em>FIP1L1::PDGFRA</em> mutation) include <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid84">84</a>], <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (useful in patients with eosinophilic vasculitis) [<a href="#rid84">84,85</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid26">26,86</a>], <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> [<a href="#rid87">87</a>], Janus kinase (JAK) inhibitors, and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. Agents that have been tried in small numbers of patients but are rarely used include <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> [<a href="#rid88">88</a>], <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid89">89</a>], and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) [<a href="#rid90">90</a>].</p><p>In most cases, therapy with chemotherapeutics and immunosuppressive agents should be aimed at controlling organ damage rather than eradicating eosinophilia. Chronic maintenance regimens are more effective and less toxic than courses of aggressive therapy aimed at inducing a hematologic remission of disease [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H2917741427"><span class="h4">Alemtuzumab</span><span class="headingEndMark"> — </span>Some cases of HES will respond to the anti-CD52 antibody <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>. However, treatment with alemtuzumab is not curative, disease recurs once treatment is interrupted, and severe toxicity (eg, profound immunosuppression) precludes long-term administration. Alemtuzumab has been withdrawn from the United States market but remains accessible through a distribution program for the treatment of several hematologic malignancies [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H3333166478"><span class="h4">JAK inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> and <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>, inhibitors of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, have shown efficacy in steroid-refractory HES. (See <a class="local">'Choice of therapy'</a> above.)</p><p><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> and <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a> were administered to five patients with either L-HES or idiopathic HES presenting with cutaneous lesions that had not responded adequately to glucocorticoids (and other immunosuppressive agents in three cases). A clinical response and a biologic response (ie, reduction of eosinophilia) was observed in all cases, which allowed for withdrawal of glucocorticoid therapy in all cases but one [<a href="#rid93">93</a>]. This is consistent with another paper reporting a gain-of-function mutation in STAT3 in CD3–CD4+ clonal T cells isolated from one patient with L-HES, leading to overproduction of eosinophil-promoting Th2 cytokines [<a href="#rid94">94</a>]. Minor infections were the only observed adverse events, but follow-up was short (3 to 13 months). (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'T cell lymphocytic variants'</a>.)</p><p class="headingAnchor" id="H1983031928"><span class="h2">Other HES variants</span><span class="headingEndMark"> — </span>Other variants of HES are familial HE, organ-restricted HES, episodic angioedema and eosinophilia (Gleich syndrome), and overlap HES  (<a class="graphic graphic_table graphicRef116201" href="/z/d/graphic/116201.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with familial HE do not require treatment if there is no evidence of end-organ damage [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overlap HES</strong> – Overlap HES refers to eosinophilic syndromes for which the syndrome definition overlaps with that of HES. These include single organ-restricted disorders, such as eosinophilic gastrointestinal diseases (EGID), chronic eosinophilic pneumonia, eosinophilic fasciitis [<a href="#rid96">96</a>], eosinophilic cellulitis (Wells syndrome) [<a href="#rid97">97,98</a>], and eosinophilic cystitis [<a href="#rid99">99-101</a>], as well as multisystem disorders, such as EGPA. Although glucocorticoids are the cornerstone of therapy for many of these disorders, therapeutic choices are guided by the specific overlap syndrome (for example, swallowed steroids or dietary therapy are often used for EGID overlap). Chronic eosinophilic pneumonia has been reported to respond well to <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> in several small case series [<a href="#rid102">102-107</a>]. (See  <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">"Eosinophilic gastrointestinal diseases"</a> and  <a class="medical medical_review" href="/z/d/html/4360.html" rel="external">"Chronic eosinophilic pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Episodic angioedema with eosinophilia (Gleich syndrome) </strong>– This syndrome is characterized by recurrent episodes of multilineage cycling and angioedema that occur approximately every month in the absence of therapy. Accompanying symptoms can include urticaria, fever, significant weight gain, and lymphadenopathy. Elevated serum immunoglobulin M (IgM) and clonal lymphocytes that express CD4 but not CD3 are typical, but these findings also cycle and can be missed [<a href="#rid108">108</a>]. Although most patients respond to intermittent glucocorticoid therapy, some require daily glucocorticoids and/or second-line agents, including <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> [<a href="#rid109">109-111</a>]. Rarely, patients progress to noncyclic HES and more serious end-organ damage [<a href="#rid112">112</a>].</p><p></p><p class="headingAnchor" id="H3346809101"><span class="h1">INVESTIGATIONAL AGENTS</span><span class="headingEndMark"> — </span>Several [<a href="#rid113">113</a>] investigational agents have been tried in patients with HES who have failed other therapies. Clinical trials in HES patients have investigated treatment with anti-IL-5 (<a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>) and anti-IL-5 receptor (<a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>) antibodies [<a href="#rid114">114,115</a>] and a small molecule of unknown target (dexpramipexole) [<a href="#rid116">116-118</a>].  </p><p>Clinical trials investigating other targeted therapies may be appropriate for patients with hypereosinophilia (HE) and myeloid features with none of the well-characterized chromosomal rearrangements. In the United States, additional information and instructions for referring a patient to an appropriate research center can be obtained from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=NK91I08KOJ1eJ1hT1o%2FoHgJu4vbbEBRl2V0d48fIIMDpbZTpeZvuNaOE2M5VxYDS&amp;TOPIC_ID=2210" target="_blank">United States National Institutes of Health</a>.</p><p class="headingAnchor" id="H1136376790"><span class="h1">PROBLEM-SPECIFIC INTERVENTIONS</span><span class="headingEndMark"> — </span>Various interventions may be needed for organ-specific involvement.</p><p class="headingAnchor" id="H1551656837"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Valve replacement or repair, endomyocardectomy, or thrombectomy can provide benefit to patients with HES who develop valvular compromise or endomyocardial thrombosis or fibrosis [<a href="#rid5">5</a>]. Valve replacement with a bioprosthesis, in contrast to a mechanical valve, is indicated, because thrombosis of mechanical valves has occurred despite therapeutic anticoagulation in patients in whom eosinophilia recurs or cannot be controlled [<a href="#rid119">119</a>]. Of note, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> therapy in patients with Fip1-like1-platelet-derived growth factor receptor alpha (<em>FIP1L1::PDGFRA</em>)-associated HES may arrest progression of endomyocardial fibrosis but does not reverse damage unless initiated before the occurrence of structural abnormalities.</p><p class="headingAnchor" id="H3848736822"><span class="h2">Anticoagulation</span><span class="headingEndMark"> — </span>Anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and/or antiplatelet agents is often instituted once an embolic event has occurred. Warfarin is usually initiated for a mural thrombus in the heart or venous thrombus in an intracranial sinus. However, there is no consensus on the target international normalized ratio (INR). Furthermore, thrombus formation may begin at altered endomyocardial or endothelial sites, so it may not be suppressed by systemic anticoagulation when it is a consequence of local and not systemic proclivity to thrombosis. Anticoagulation is not usually initiated empirically in the absence of an event, as emboli can recur in adequately anticoagulated patients, and efficacy is not certain [<a href="#rid120">120</a>]. Once the eosinophilia is controlled durably with stable therapy, the need for continued anticoagulation should be determined using the same criteria used for patients without eosinophilia. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H2545474288"><span class="h2">Hypersplenism</span><span class="headingEndMark"> — </span>Splenectomy may be indicated in patients with hypersplenism and/or pain due to splenic distension or infarcts, although it is not indicated in the routine management of HES. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Abscess and infarction'</a>.)</p><p class="headingAnchor" id="H3015630788"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>All patients with HES require monitoring for side effects of therapy, organ involvement, and disease progression. In addition, clinicians must be vigilant for signs or symptoms of thrombotic complications. Monitoring of patients with HES must be individualized. Regular eosinophil counts are recommended with additional testing depending on the therapeutic agent being used and the end organs involved.</p><p class="headingAnchor" id="H4147214034"><span class="h2">Frequency</span><span class="headingEndMark"> — </span>The frequency of monitoring is also variable. As examples, patients with continued symptoms and eosinophilia despite aggressive therapy may need to be evaluated weekly, while stable patients on chronic low-dose glucocorticoids could be appropriately followed every 6 to 12 months.</p><p class="headingAnchor" id="H3069366523"><span class="h2">Monitoring for organ involvement</span><span class="headingEndMark"> — </span>End-organ involvement may develop insidiously and is not correlated with the degree of blood eosinophilia. Therefore, all patients, including those who are asymptomatic, should be re-evaluated every three months for the first one to two years after diagnosis with a review of systems to detect new signs or symptoms.</p><p>A complete blood count and differential, as well as blood chemistries (including hepatic enzymes and renal function) and troponin should be obtained at each of these visits. If new symptoms or signs are present, the tests listed below should also be performed:</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (to evaluate for conduction abnormalities or arrhythmia) and echocardiogram. If serum troponin is elevated and/or if echocardiogram is abnormal, cardiac magnetic resonance imaging (MRI) should be obtained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary evaluations, including chest computed tomography (CT) and pulmonary function tests as indicated.</p><p></p><p>Additional testing should be based on signs and symptoms and prior evidence of organ involvement.</p><p>Issues relevant to specific subgroups include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <em>FIP1L1::PDGFRA</em> mutation on <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> should be monitored approximately every three months with a complete blood count with differential and a liver profile once in stable clinical, hematologic, and molecular remission. Troponin should be followed as well, as drug-associated cardiomyopathy has been reported as a rare complication of imatinib in patients being treated for chronic myeloid leukemia (CML) [<a href="#rid121">121</a>]. Optimally, testing for the <em>FIP1L1::PDFGRA</em> transcript by polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) should be repeated every three to four months, as this is an early marker of therapeutic failure. In patients with no new symptoms, a yearly echocardiogram is suggested.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with lymphocytic variants of HES (L-HES) should be evaluated every three to six months with a clinical examination for lymphadenopathy, complete blood count (looking for lymphocytosis and other lineage involvement), serum lactate dehydrogenase, and flow cytometry to quantify the abnormal clone. Patients with an increase in the proportion of aberrant T cells on flow cytometry (eg, CD3–CD4+ cells) are at increased risk for progression to lymphoma and should undergo a repeat bone marrow biopsy, including a karyotype analysis [<a href="#rid122">122</a>]. Enlarged lymph nodes and changing/suspicious skin lesions should also be biopsied. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H997455221"><span class="h2">Vigilance for thrombotic complications</span><span class="headingEndMark"> — </span>Thrombotic and thromboembolic events are a major cause of morbidity among patients with HES, and a high degree of suspicion for these complications must be maintained. The available series suggest that about one-quarter of patients with HES develop thromboembolic complications [<a href="#rid120">120,123-125</a>]. These complications are reviewed separately. </p><p>Prophylactic use of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and/or antiplatelet agents is <strong>not</strong> recommended in the absence of documented thrombi, in part because the effectiveness of these interventions is unclear. Recurrent thrombotic events have occurred in adequately anticoagulated HES patients [<a href="#rid123">123</a>]. (See <a class="local">'Anticoagulation'</a> above.)</p><p class="headingAnchor" id="H967714991"><span class="h1">PLANNING FOR DISEASE PROGRESSION</span><span class="headingEndMark"> — </span>Early human leukocyte antigen (HLA) typing for possible allogeneic hematopoietic cell transplantation should be considered for patients with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Cytogenetic abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Potentially life-threatening end-organ involvement (especially cardiac or central nervous system [CNS] involvement)</p><p class="bulletIndent1"><span class="glyph">●</span>Features of myeloid disease (eg, dysplastic eosinophils, anemia, thrombocytopenia, splenomegaly, elevated serum B12 or tryptase)</p><p></p><p>(See <a class="local">'Hematopoietic cell transplantation'</a> below.)</p><p class="headingAnchor" id="H323159568"><span class="h1">HEMATOPOIETIC CELL TRANSPLANTATION</span><span class="headingEndMark"> — </span>There is limited experience in the use of allogeneic hematopoietic cell transplantation (HCT), including nonmyeloablative HCT, to treat HES [<a href="#rid126">126-132</a>]. This intervention may be useful in patients with treatment refractory HES, particularly those rare patients with imatinib-resistant <em>PDGFRA</em>-associated disease, although the risks of the procedure do not justify its routine use. Transplantation should also be considered for patients with lymphocytic variants of HES (L-HES) who develop T cell lymphoma, which may be resistant to classic chemotherapeutic regimens. (See  <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">"Initial treatment of peripheral T cell lymphoma"</a>.)</p><p>HCT is associated with more morbidity than medical therapy, but for those patients who fail the available pharmacologic therapies, it offers the potential for long-term remission and possible cure [<a href="#rid131">131</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One patient with a clonal population of CD3–CD4+ T cells (L-HES) and an intraventricular thrombus was successfully treated with reduced-intensity peripheral blood progenitor cell transplantation (HLA identical brother) and remained in remission 30 months later [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, two patients were treated with HCT (one with an HLA-matched unrelated donor and the other with a related donor) and remained in remission 10 months after transplantation [<a href="#rid130">130</a>].</p><p></p><p>The conditioning regimen used in these cases and in the above mentioned case of L-HES was <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> and <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>.</p><p>The eligibility for allogeneic transplantation varies by institution. General eligibility criteria are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Features that portend a better prognosis include the absence of cardiac or neurologic involvement, lower eosinophil counts, and steroid-responsiveness [<a href="#rid4">4,5,16,134</a>].</p><p>Lymphocytic variants of HES (L-HES) usually represent benign lymphoproliferative disorders, although progression toward full blown T cell lymphoma has been reported in approximately 10 percent of cases [<a href="#rid62">62,135-138</a>]. Malignant progression in such patients may be heralded by the appearance of cytogenetic changes [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H33"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Initial case series of HES showed a poor prognosis, with a mean survival of nine months and a three-year survival of only 12 percent [<a href="#rid91">91</a>]. However, most patients in early series presented with advanced disease and significant cardiovascular compromise. Many deaths that were due to end-stage heart failure or other complications of endomyocardial damage in the past, are amenable to improvements in medical and surgical management [<a href="#rid91">91</a>]. Furthermore, patients with Fip1-like1-platelet-derived growth factor receptor alpha (<em>FIP1L1::PDGFRA</em>)-positive HES, who had an extremely poor prognosis prior to the availability of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> therapy, were likely over-represented in these series.</p><p>Over time, earlier diagnosis of HES, close clinical and echocardiographic monitoring for heart disease, and improved medical and surgical management of cardiac complications have improved the longevity of HES patients. A 1989 French series of 40 patients (including 17 with an associated myeloproliferative syndrome) reported prior to the availability of testing for mutations in <em>PDGFRA</em> noted an 80 percent survival at 5 years and a 42 percent survival at 15 years [<a href="#rid139">139</a>]. In a subsequent retrospective study of 44 patients with <em>FIP1L1::PDGFRA</em>-positive disease treated with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, all but one were alive at a median follow-up of 52 months [<a href="#rid22">22</a>]. While prospective studies are needed to confirm the good prognosis, these results suggest that the introduction of targeted therapies, including imatinib, has further reduced overall mortality in patients presenting with HES.</p><p class="headingAnchor" id="H427171546"><span class="h1">SPECIAL CONSIDERATIONS DURING THE COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>The coronavirus disease 2019 (COVID-19) pandemic has increased the complexity of cancer care. Important issues include balancing the risk from treatment delay versus harm from COVID-19, ways to minimize negative impacts of social distancing during care delivery, and appropriately and fairly allocating limited health care resources. Additionally, immunocompromised patients are candidates for a modified vaccination schedule  (<a class="graphic graphic_figure graphicRef138339" href="/z/d/graphic/138339.html" rel="external">figure 1</a>), other preventive strategies (including pre-exposure prophylaxis), and the early initiation of COVID-directed therapy. These issues and recommendations for cancer care during the COVID-19 pandemic are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic therapy for the hypereosinophilic syndromes (HES) is determined by a number of factors, including the severity of patient's signs and symptoms, whether the clinical presentation is suggestive of a myeloid neoplasm, and the results of molecular studies (eg, mutational analysis for the presence of <em>FIP1L1::PDGFRA</em>-associated disease). The goals of therapy are reduction of the absolute eosinophil count (AEC), amelioration of signs and symptoms, and prevention of disease progression. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the rare patient who presents with very high eosinophil levels, symptoms of leukostasis, or potentially life-threatening complications of hypereosinophilia (HE) (eg, acute heart failure, thromboembolic events), immediate therapy should be initiated to rapidly reduce counts. We suggest high-dose intravenous glucocorticoids as an initial intervention  (<a class="graphic graphic_algorithm graphicRef103933" href="/z/d/graphic/103933.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Doses ranging from 1 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to 1 gram of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> have been used successfully. Important tests to exclude other disorders in the differential diagnosis and to differentiate disease variants should be performed prior to glucocorticoid administration, although they should not delay treatment. Patients at risk for infection with <em>Strongyloides</em> should be treated with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>, concomitantly with glucocorticoids. (See <a class="local">'Immediate treatment for severe disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients require baseline testing, some of which should be done before initiating therapy, as glucocorticoids, in particular, can alter the results. Once treatment has been initiated, all patients require periodic monitoring for organ involvement, which is not correlated with the degree of blood eosinophilia and may develop insidiously. Patients with aggressive disease should undergo human leukocyte antigen (HLA) typing in preparation for possible allogeneic hematopoietic cell transplantation (HCT). (See <a class="local">'Studies to obtain urgently'</a> above and <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all patients with the <em>FIP1L1::PDGFRA</em> mutation (even if asymptomatic), we recommend <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate for initial therapy, in preference to other available agents (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We also suggest the use of imatinib for patients with HES with myeloproliferative features in the absence of the <em>FIP1L1::PDGFRA</em> mutation who have failed initial treatment with glucocorticoids and/or as glucocorticoid-sparing treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We begin imatinib at a dose of 400 mg/day. Patients with cardiac involvement should receive glucocorticoids (1 to 2 mg/kg daily for one to four weeks) at the same time that imatinib is initiated to prevent acute cardiac injury. Typically, symptoms improve, and eosinophil counts normalize within one to two weeks in patients with the <em>FIP1L1::PDGFRA</em> mutation. In others, this may take longer and/or require a higher dose of imatinib. Thereafter, the dose is reduced to the lowest effective dose that maintains molecular remission and continued for a minimum duration of seven years. It may be possible to withdraw treatment thereafter, provided patients are followed regularly to detect early recurrence of the fusion gene, as prolonged treatment-free remission has been observed. (See <a class="local">'Imatinib mesylate'</a> above and <a class="local">'Myeloid variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with the <em>FIP1L1::PDGFRA</em> mutation who develop secondary resistance to <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate or are intolerant of it, we suggest a trial of another tyrosine kinase inhibitor, such as <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a>, <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a>, or <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If not already pursued, referral to a center with expertise in HES should be arranged. (See <a class="local">'Imatinib-resistant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For symptomatic patients with HES without myeloid features, including those with lymphocytic variants of HES (L-HES) and idiopathic HES, we recommend systemic glucocorticoids as initial therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We typically administer <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 20 to 60 mg daily, for one to two weeks. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If blood eosinophilia is suppressed, doses are slowly tapered to an alternate-day schedule of the lowest dose that maintains control of the eosinophil count and clinical disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If blood eosinophilia is not suppressed or if the dose of glucocorticoids required to maintain a response is judged excessive (ie, either &gt;10 mg/day and/or poor tolerance), a second agent should be added. The choice of second-line agent depends on the clinical features and suspected underlying cause, as described above. (See <a class="local">'Steroid-sparing and second-line therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients may require interventions for specific cardiac complications, such as valve replacement or repair, endomyocardectomy or thrombectomy, or anticoagulation if embolic events develop. (See <a class="local">'Problem-specific interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For HES patients (with or without the <em>FIP1L1::PDGFRA</em> fusion) who fail pharmacologic management, allogeneic HCT offers a chance of long-term remission. (See <a class="local">'Hematopoietic cell transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H437646406"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kuang FL, Klion AD. Biologic Agents for the Treatment of Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract 2017; 5:1502.</a></li><li><a class="nounderline abstract_t">Klion AD. How I treat hypereosinophilic syndromes. Blood 2015; 126:1069.</a></li><li><a class="nounderline abstract_t">McMillan HJ, Johnston DL, Doja A. Watershed infarction due to acute hypereosinophilia. Neurology 2008; 70:80.</a></li><li><a class="nounderline abstract_t">Parrillo JE, Lawley TJ, Frank MM, et al. Immunologic reactivity in the hypereosinophilic syndrome. J Allergy Clin Immunol 1979; 64:113.</a></li><li><a class="nounderline abstract_t">Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.</a></li><li><a class="nounderline abstract_t">Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2021; 73:1366.</a></li><li><a class="nounderline abstract_t">Bettiol A, Urban ML, Bello F, et al. Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Ann Rheum Dis 2022; 81:1769.</a></li><li><a class="nounderline abstract_t">Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292.</a></li><li><a class="nounderline abstract_t">Khoury P, Abiodun AO, Holland-Thomas N, et al. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids. J Allergy Clin Immunol Pract 2018; 6:190.</a></li><li><a class="nounderline abstract_t">Roufosse F, Heimann P, Lambert F, et al. Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association. Respiration 2016; 91:374.</a></li><li><a class="nounderline abstract_t">Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120:680.</a></li><li><a class="nounderline abstract_t">Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201.</a></li><li><a class="nounderline abstract_t">Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003; 100:7830.</a></li><li><a class="nounderline abstract_t">Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101:4714.</a></li><li><a class="nounderline abstract_t">Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101:3391.</a></li><li><a class="nounderline abstract_t">Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660.</a></li><li><a class="nounderline abstract_t">Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473.</a></li><li><a class="nounderline abstract_t">Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635.</a></li><li><a class="nounderline abstract_t">Cervetti G, Galimberti S, Carulli G, Petrini M. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. Leuk Res 2005; 29:1097.</a></li><li><a class="nounderline abstract_t">von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19:286.</a></li><li><a class="nounderline abstract_t">Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92:1173.</a></li><li><a class="nounderline abstract_t">Legrand F, Renneville A, Macintyre E, et al. The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore) 2013.</a></li><li><a class="nounderline abstract_t">Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456.</a></li><li><a class="nounderline abstract_t">Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18:734.</a></li><li><a class="nounderline abstract_t">Rohmer J, Couteau-Chardon A, Trichereau J, et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. Am J Hematol 2020; 95:1314.</a></li><li><a class="nounderline abstract_t">Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319.</a></li><li><a class="nounderline abstract_t">Suzuki R, Kobayashi C, Sakai A, et al. Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 2015; 37:e368.</a></li><li class="breakAll">Re-institution of therapy following certain severe adverse effects is addressed in the package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf (Accessed on December 01, 2017).</li><li><a class="nounderline abstract_t">Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008; 121:1054.</a></li><li><a class="nounderline abstract_t">Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008; 122:425.</a></li><li><a class="nounderline abstract_t">Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008; 143:707.</a></li><li><a class="nounderline abstract_t">Helbig G, Moskwa A, Swiderska A, et al. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up. Br J Haematol 2009; 145:132.</a></li><li><a class="nounderline abstract_t">Intermesoli T, Delaini F, Acerboni S, et al. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol 2009; 147:681.</a></li><li><a class="nounderline abstract_t">Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110:3552.</a></li><li><a class="nounderline abstract_t">Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003; 40:21.</a></li><li><a class="nounderline abstract_t">Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505.</a></li><li><a class="nounderline abstract_t">Mariani S, Basciani S, Fabbri A, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril 2011; 95:1120.e15.</a></li><li><a class="nounderline abstract_t">Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004; 351:2134.</a></li><li><a class="nounderline abstract_t">Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 2009; 7:1050.</a></li><li><a class="nounderline abstract_t">Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007; 137:374.</a></li><li><a class="nounderline abstract_t">Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 2008; 358:1079.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Takebayashi C, Miyata S, et al. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia. Intern Med 2009; 48:369.</a></li><li><a class="nounderline abstract_t">Helbig G, Soja A, Świderska A, et al. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Leuk Lymphoma 2016; 57:708.</a></li><li><a class="nounderline abstract_t">Qu SQ, Qin TJ, Xu ZF, et al. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget 2016; 7:33229.</a></li><li><a class="nounderline abstract_t">Khoury P, Desmond R, Pabon A, et al. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy 2016; 71:803.</a></li><li class="breakAll">Testing is available from Mayo Clinic Laboratories.</li><li><a class="nounderline abstract_t">Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23:845.</a></li><li><a class="nounderline abstract_t">Baumgartner C, Gleixner KV, Peter B, et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008; 36:1244.</a></li><li><a class="nounderline abstract_t">Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106:3206.</a></li><li><a class="nounderline abstract_t">Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108:1374.</a></li><li><a class="nounderline abstract_t">Hochhaus A, le Coutre PD, Kantarjian HM, et al. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 2013; 139:1985.</a></li><li><a class="nounderline abstract_t">Jain N, Cortes J, Quintás-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 2009; 33:837.</a></li><li><a class="nounderline abstract_t">Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827.</a></li><li><a class="nounderline abstract_t">Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574.</a></li><li><a class="nounderline abstract_t">Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138:77.</a></li><li><a class="nounderline abstract_t">Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 2009; 33:1127.</a></li><li><a class="nounderline abstract_t">Magnusson MK, Meade KE, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 2002; 100:1088.</a></li><li><a class="nounderline abstract_t">Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347:481.</a></li><li><a class="nounderline abstract_t">David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109:61.</a></li><li><a class="nounderline abstract_t">Chen YY, Khoury P, Ware JM, et al. Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol 2014; 133:1195.</a></li><li><a class="nounderline abstract_t">Kuang FL, Fay MP, Ware J, et al. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. J Allergy Clin Immunol Pract 2018; 6:1518.</a></li><li><a class="nounderline abstract_t">Carpentier C, Verbanck S, Schandené L, et al. Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients. Front Immunol 2020; 11:1765.</a></li><li><a class="nounderline abstract_t">Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 146:1397.</a></li><li><a class="nounderline abstract_t">Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215.</a></li><li><a class="nounderline abstract_t">Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013; 131:461.</a></li><li><a class="nounderline abstract_t">Plötz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2334.</a></li><li><a class="nounderline abstract_t">Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113:115.</a></li><li><a class="nounderline abstract_t">Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008; 121:1473.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761122s005lbl.pdf (Accessed on September 29, 2020).</li><li><a class="nounderline abstract_t">Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58:1021.</a></li><li><a class="nounderline abstract_t">Dahabreh IJ, Giannouli S, Zoi C, et al. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 2007; 86:344.</a></li><li><a class="nounderline abstract_t">Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114:26.</a></li><li><a class="nounderline abstract_t">Schandené L, Roufosse F, de Lavareille A, et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000; 96:4285.</a></li><li><a class="nounderline abstract_t">Lefèvre G, Copin MC, Staumont-Sallé D, et al. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore) 2014; 93:255.</a></li><li><a class="nounderline abstract_t">Butterfield JH, Weiler CR. Treatment of hypereosinophilic syndromes--the first 100 years. Semin Hematol 2012; 49:182.</a></li><li><a class="nounderline abstract_t">Malbrain ML, Van den Bergh H, Zachée P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92:176.</a></li><li><a class="nounderline abstract_t">Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994; 121:648.</a></li><li><a class="nounderline abstract_t">Bockenstedt PL, Santinga JT, Bolling SF. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994; 45:248.</a></li><li><a class="nounderline abstract_t">Canonica GW, Passalacqua G, Pronzato C, et al. Effective long-term alpha-interferon treatment for hypereosinophilic syndrome. J Allergy Clin Immunol 1995; 96:131.</a></li><li><a class="nounderline abstract_t">Choi C, Moller D, Tan J, et al. Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome. Br J Haematol 2020; 188:e68.</a></li><li><a class="nounderline abstract_t">Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673.</a></li><li><a class="nounderline abstract_t">Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093.</a></li><li><a class="nounderline abstract_t">Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31:686.</a></li><li><a class="nounderline abstract_t">Vaklavas C, Tefferi A, Butterfield J, et al. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007; 31:691.</a></li><li><a class="nounderline abstract_t">Dunogué B, Pagnoux C, Guillevin L. Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med 2011; 32:298.</a></li><li><a class="nounderline abstract_t">Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics 1997; 99:630.</a></li><li><a class="nounderline abstract_t">Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004; 127:477.</a></li><li><a class="nounderline abstract_t">Razaq W, Beautyman E. Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide. Am J Ther 2009; 16:68.</a></li><li><a class="nounderline abstract_t">van Grotel M, de Hoog M, de Krijger RR, et al. Hypereosinophilic syndrome in children. Leuk Res 2012; 36:1249.</a></li><li><a class="nounderline abstract_t">Dou C, Chen LYC, Dutz JP. Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid. JAAD Case Rep 2019; 5:660.</a></li><li><a class="nounderline abstract_t">Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf (Accessed on December 01, 2017).</li><li><a class="nounderline abstract_t">King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. J Invest Dermatol 2017; 137:951.</a></li><li><a class="nounderline abstract_t">Walker S, Wang C, Walradt T, et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 2016; 127:948.</a></li><li><a class="nounderline abstract_t">Klion AD, Law MA, Riemenschneider W, et al. Familial eosinophilia: a benign disorder? Blood 2004; 103:4050.</a></li><li><a class="nounderline abstract_t">Mazori DR, Femia AN, Vleugels RA. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep 2017; 19:74.</a></li><li><a class="nounderline abstract_t">Räßler F, Lukács J, Elsner P. Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review. J Eur Acad Dermatol Venereol 2016; 30:1465.</a></li><li><a class="nounderline abstract_t">Puzas ÁI, Álvarez LM, Menéndez ÁF, et al. Wells' Syndrome Successfully Treated with Colchicine. Case Rep Dermatol 2017; 9:65.</a></li><li><a class="nounderline abstract_t">Li G, Cai B, Song H, Yang Z. Clinical and radiological character of eosinophilic cystitis. Int J Clin Exp Med 2015; 8:533.</a></li><li><a class="nounderline abstract_t">Itano NM, Malek RS. Eosinophilic cystitis in adults. J Urol 2001; 165:805.</a></li><li><a class="nounderline abstract_t">Teegavarapu PS, Sahai A, Chandra A, et al. Eosinophilic cystitis and its management. Int J Clin Pract 2005; 59:356.</a></li><li><a class="nounderline abstract_t">Brenard E, Pilette C, Dahlqvist C, et al. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. Lung 2020; 198:355.</a></li><li><a class="nounderline abstract_t">Tashiro H, Takahashi K, Kurihara Y, et al. Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series. J Asthma Allergy 2022; 15:169.</a></li><li><a class="nounderline abstract_t">Kisling A, Jones J, Hixson C, et al. Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. Drugs Context 2020; 9.</a></li><li><a class="nounderline abstract_t">Ciuffreda M, Caruso C, Romano A, Sarni A. Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: A case report. J Allergy Clin Immunol Pract 2020; 8:3640.</a></li><li><a class="nounderline abstract_t">Sarkis E, Patel S, Burns K, et al. Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia. J Asthma 2020; 57:82.</a></li><li><a class="nounderline abstract_t">Shimizu Y, Kurosawa M, Sutoh Y, Sutoh E. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia. J Investig Allergol Clin Immunol 2020; 30:154.</a></li><li><a class="nounderline abstract_t">Khoury P, Herold J, Alpaugh A, et al. Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica 2015; 100:300.</a></li><li><a class="nounderline abstract_t">Roufosse F, de Leval L, van Krieken H, van Deuren M. Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2015; 56:1891.</a></li><li><a class="nounderline abstract_t">Matucci A, Liotta F, Vivarelli E, et al. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome. Front Immunol 2018; 9:1198.</a></li><li><a class="nounderline abstract_t">Abisror N, Mekinian A, Dechartres A, et al. Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich syndrome): Frequency, clinical implication, and prognosis. J Am Acad Dermatol 2023; 88:e243.</a></li><li><a class="nounderline abstract_t">Wright BL, Butterfield JH, Leiferman KM, Gleich GJ. Development of eosinophilic endomyocardial disease in a patient with episodic angioedema and eosinophilia. J Allergy Clin Immunol Pract 2016; 4:336.</a></li><li><a class="nounderline abstract_t">Dellon ES, Peterson KA, Murray JA, et al. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. N Engl J Med 2020; 383:1624.</a></li><li><a class="nounderline abstract_t">FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128.</a></li><li><a class="nounderline abstract_t">Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome. N Engl J Med 2019; 380:1336.</a></li><li><a class="nounderline abstract_t">Roufosse F. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. Front Med (Lausanne) 2018; 5:49.</a></li><li><a class="nounderline abstract_t">Gleich GJ. Dexpramipexole: a new antieosinophil drug? Blood 2018; 132:461.</a></li><li><a class="nounderline abstract_t">Panch SR, Bozik ME, Brown T, et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood 2018; 132:501.</a></li><li><a class="nounderline abstract_t">Boustany CW Jr, Murphy GW, Hicks GL Jr. Mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 1991; 51:1007.</a></li><li><a class="nounderline abstract_t">Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:457.</a></li><li><a class="nounderline abstract_t">Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233.</a></li><li><a class="nounderline abstract_t">Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:389.</a></li><li><a class="nounderline abstract_t">Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52:1.</a></li><li><a class="nounderline abstract_t">Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol 1983; 52:321.</a></li><li><a class="nounderline abstract_t">Parrillo JE, Borer JS, Henry WL, et al. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med 1979; 67:572.</a></li><li><a class="nounderline abstract_t">Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996; 51:164.</a></li><li><a class="nounderline abstract_t">Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol 1995; 90:213.</a></li><li><a class="nounderline abstract_t">Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:647.</a></li><li><a class="nounderline abstract_t">Archimbaud E, Guyotat D, Guillaume C, et al. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol 1988; 27:302.</a></li><li><a class="nounderline abstract_t">Ueno NT, Anagnostopoulos A, Rondón G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119:131.</a></li><li><a class="nounderline abstract_t">Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006; 38:319.</a></li><li><a class="nounderline abstract_t">Fathi AT, Dec GW Jr, Richter JM, et al. Case records of the Massachusetts General Hospital. Case 7-2014. A 27-year-old man with diarrhea, fatigue, and eosinophilia. N Engl J Med 2014; 370:861.</a></li><li><a class="nounderline abstract_t">Bergua JM, Prieto-Pliego E, Román-Barberá A, et al. Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation. Ann Hematol 2008; 87:937.</a></li><li><a class="nounderline abstract_t">Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978; 89:167.</a></li><li><a class="nounderline abstract_t">Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169.</a></li><li><a class="nounderline abstract_t">Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.</a></li><li><a class="nounderline abstract_t">Roufosse F, Schandené L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540.</a></li><li><a class="nounderline abstract_t">Lefèvre G, Copin MC, Roumier C, et al. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica 2015; 100:1086.</a></li><li><a class="nounderline abstract_t">Lefebvre C, Bletry O, Degoulet P, et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann Med Interne (Paris) 1989; 140:253.</a></li></ol></div><div id="topicVersionRevision">Topic 2210 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122152" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Biologic Agents for the Treatment of Hypereosinophilic Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964669" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : How I treat hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166711" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Watershed infarction due to acute hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313411" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Immunologic reactivity in the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180373" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235894" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35850947" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750989" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28757367" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164940" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628645" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660384" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808148" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595304" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506022" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12676775" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504092" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299092" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16038739" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618966" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666373" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23982058" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568908" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14973504" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32720700" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910029" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25929609" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25929609" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18234315" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678345" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18950453" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120352" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19735261" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709602" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783371" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Imatinib treatment: specific issues related to safety, fertility, and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322153" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effects of imatinib on pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888557" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15537917" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19930974" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Issues of imatinib and pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408403" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322295" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary ovarian insufficiency associated with imatinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252364" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26430910" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27120808" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797802" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797802" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19212337" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18619723" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030188" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645167" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24057647" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19013640" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498388" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687085" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555450" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144405" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130532" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181402" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16960151" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23987798" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Marked and persistent eosinophilia in the absence of clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29751154" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32849632" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956756" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344568" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of patients with the hypereosinophilic syndrome with mepolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040887" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668459" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699394" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410960" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410960" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7197566" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18004179" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15995323" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110703" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398061" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22449628" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of hypereosinophilic syndromes--the first 100 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562393" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944072" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296798" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7622756" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effective long-term alpha-interferon treatment for hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31721154" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180753" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recent advances in pathogenesis and management of hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842979" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12901973" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17095087" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21674415" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093318" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15566349" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142161" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727506" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hypereosinophilic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31388532" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090795" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090795" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27887955" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702067" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14988154" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Familial eosinophilia: a benign disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29101481" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27357601" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28868003" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Wells' Syndrome Successfully Treated with Colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785027" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical and radiological character of eosinophilic cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176473" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Eosinophilic cystitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857336" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Eosinophilic cystitis and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052155" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35177908" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32884574" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673881" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30444149" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31778113" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527564" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25330447" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29896203" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30738125" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich syndrome): Frequency, clinical implication, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563671" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Development of eosinophilic endomyocardial disease in a patient with episodic angioedema and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085861" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609406" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Benralizumab, an anti-interleukin-5 receptorαmonoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30943337" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29682504" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30072411" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Dexpramipexole: a new antieosinophil drug?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29739754" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039298" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Mitral valve replacement in idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868859" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cardiovascular manifestations of hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449798" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Congestive heart failure is a rare event in patients receiving imatinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868856" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Lymphocytic variant hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6878618" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Clinical features of fifteen patients with the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6869280" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/495628" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8579059" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7786788" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655396" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281451" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12358917" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16819435" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24571759" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Case records of the Massachusetts General Hospital. Case 7-2014. A 27-year-old man with diarrhea, fatigue, and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18521601" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/677578" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Therapy of the hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525672" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : The hypereosinophilic syndrome revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511609" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886202" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25682606" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2675714" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases].</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
